A new trading day began on Monday, with Viking Therapeutics Inc (NASDAQ: VKTX) stock price down -13.36% from the previous day of trading, before settling in for the closing price of $72.88. VKTX’s price has ranged from $9.34 to $99.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -6.59%. With a float of $107.93 million, this company’s outstanding shares have now reached $111.44 million.
The extent of productivity of a business whose workforce counts for 27 workers is very important to gauge. In terms of profitability, gross margin is 28.9%, operating margin of -30726.61%, and the pretax margin is -22741.06%.
Viking Therapeutics Inc (VKTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Viking Therapeutics Inc is 3.14%, while institutional ownership is 74.57%. The most recent insider transaction that took place on Oct 28 ’24, was worth 10,089,164. In this transaction Chief Financial Officer of this company sold 131,687 shares at a rate of $76.61, taking the stock ownership to the 149,366 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Officer proposed sale 131,687 for $78.03, making the entire transaction worth $10,275,537.
Viking Therapeutics Inc (VKTX) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.25 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 40.00% during the next five years compared to -18.89% drop over the previous five years of trading.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Here are Viking Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 36.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -1.51 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
The latest stats from [Viking Therapeutics Inc, VKTX] show that its last 5-days average volume of 8.71 million was superior to 4.49 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 43.79%. Additionally, its Average True Range was 5.19.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 47.81%, which indicates a significant increase from 14.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 110.58% in the past 14 days, which was higher than the 88.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $64.42, while its 200-day Moving Average is $60.03. Now, the first resistance to watch is $73.89. This is followed by the second major resistance level at $84.65. The third major resistance level sits at $90.19. If the price goes on to break the first support level at $57.59, it is likely to go to the next support level at $52.05. The third support level lies at $41.29 if the price breaches the second support level.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
With a market capitalization of 7.07 billion, the company has a total of 111,436K Shares Outstanding. Currently, annual sales are 0 K while annual income is -85,900 K. The company’s previous quarter sales were 0 K while its latest quarter income was -24,940 K.
